| Description | Luvadaxistat (TAK-831) is an orally active, potent and highly selective inhibitor of D-amino acid oxidase (DAAO) with an IC50 value of 14 nM for the oxidative deamination of D-serine.Luvadaxistat is used in the study of schizophrenia and cognitive disorders. |
| In vivo | 在 9-10 周龄的雄性 BALB/c 小鼠中，Luvadaxistat（0.001、0.003、0.01、0.03、0.1、0.3、1、3 mg/kg；口服；每日一次；14天）在慢性给药（0.01-3 mg/kg）时，剂量依赖性地改善了BALB/c动物的社交行为，体现在社会性互作测试中[1]。 |
| Synonyms | TAK-831, NBI 1065844 |
| molecular weight | 284.23 |
| Molecular formula | C13H11F3N2O2 |
| CAS | 1425511-32-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 10 mg/mL (35.18 mM), Sonication is recommended. |
| References | 1. Fradley R, et al. Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia. Neurochem Res. 2023 Oct;48(10):3027-3041. 2. Wang H,et al. Results of a randomized double-blind study evaluating luvadaxistat in adults with Friedreich ataxia. Ann Clin Transl Neurol. 2021 Jun;8(6):1343-1352. 3. Fradley R, et al. Correction to: Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia. Neurochem Res. 2023 Nov;48(11):3472. |